News and Press Releases

• January 25, 2023
  Nanōmix Appoints Finance Veteran Chris Hetterly as Chief Financial Officer
• November 29, 2022
  Nanōmix Enters into Distribution Agreement for the eLab System with Gepa Srl in Italy
• November 9, 2022
  Nanōmix Enters into an Exclusive Veterinary Distribution Agreement for the eLab System with Woodley Equipment Company, Ltd.
• November 4, 2022
  Nanōmix Enters into Multi-Country Distribution Agreement for the eLab System with Mast Group Limited
• October 20, 2022
  Nanōmix Enters into Distribution Agreement for the eLab System and Future New Products with Diaclinic SpA in Chile
• September 12, 2022
  Nanōmix Enters into Distribution Agreement for the eLab System and Future New Products with IPS Genomix s.a.l. in the Middle East
• September 2, 2022
  Nanōmix Announces Agreement with Mobility Health to Co-Develop a Lab Development Test for Evaluating Levels of COVID-19 Circulating Antibodies
• August 31, 2022
  Nanōmix Appoints Industry Veteran Tadd S. Lazarus, M.D., to the Board of Directors
• August 23, 2022
  Nanōmix Enters into Distribution Agreement for the eLab System and Future New Products with BIOASIA PTE LTD in Singapore
• August 18, 2022
  Nanōmix Announces ISO 13485:2016 Certification for its New Facility in San Leandro, CA
• July 27, 2022
  Nanōmix Appoints Life Sciences Executive Thomas Schlumpberger as Chief Executive Officer and Member of the Board of Directors
• July 21, 2022
  Nanōmix Announces Distribution Agreement for the eLab System with Biotron Ltd. in Israel
• July 1, 2022
  Schedule Your Demo at AACC 2022 of the Nanōmix eLab^® system. Critical Host Response Diagnostics in Minutes. Hand-held, Multiplex Immunoassay from a Single Sample.
• June 22, 2022
  Nanōmix Initiates New Clinical Study for the eLab S1 Panel
• June 14, 2022
  Nanōmix Receives IVDR Certification for the eLab Analyzer
• May 26, 2022
  Nanōmix Announces Granted CE Mark for eLab S1 Assay Panel for Whole Blood Samples
• May 23, 2022
  Nanōmix Announces Upgrade to OTCQB^® Venture Market
• May 20, 2022
  Nanōmix Receives CE Mark for its eLab COVID-19 Rapid Point-of-Care Antigen Panel
• March 25, 2022
  Nanōmix Appoints Vidur Sahney as Chief Operating Officer
• March 30, 2022
  Nanōmix Corporation Announces Securities Purchase Agreement with GHS Investments for up to $3.0 Million
• March 18, 2022
  Nanōmix Completes 1-for-173 Reverse Stock Split
• March 2, 2022
  Nanōmix to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

News Stories

• March 22, 2022
  2022 ECCMID European Congress of Clinical Microbiology & Infectious Disease
  The Company is currently scheduling demos and partner discussions for the 32nd ECCMID European Congress in Lisbon, Portugal. You may schedule a time for a demonstration.

Press Releases

• December 9, 2021
  Nanōmix Announces UK MHRA Registration for New Point of Care System
• December 2, 2021
  Nanōmix Submits Emergency Use Authorization Application for its Rapid Point- of-Care Antigen Panel to Detect COVID-19
• November 15, 2021
  Nanōmix Completes Changes to Corporate Name and Ticker Symbol
• September 9, 2021
  Schedule Your Demo at AACC 2021 of the Nanōmix eLab^® system. Critical Host Response Diagnostics in Minutes. Hand-held, Multiplex Immunoassay from a Single Sample.  (link)
• June 29, 2021
  Boston Therapeutics Announces $8.4 Million Convertible Placement in Conjunction with Nanōmix Reverse Merger  (link)
• February 9, 2021
  Nanōmix Submits Emergency Use Authorization Request to FDA for Rapid Antigen Panel to Detect COVID-19.
• January 5, 2021
  Nanōmix Selected as Finalist in XPRIZE Rapid COVID Testing Competition.  (link)

News Stories

• March 19, 2021
  Fighting for Our Lives  (link)
  With a platform already in place, Nanōmix had a significant head start. It developed a 10-minute blood test to detect the presence of antibodies in people who’ve recovered from COVID-19.

• May 29, 2020
  Five COVID-19 Test Developers to Watch  (link)
  Nanōmix is highlighted among the companies that could help provide the millions of COVID-19 tests that are needed to support safe re-opening.
• May 20, 2020
  This COVID-19 Detector Has Berkeley Lab Roots  (link)
  How an atomically thin device could become a biotech breakthrough.
• April 21, 2020
  TechNation Radio: "A 15-Minute COVID-19 Detector?"  (link)
  TechNation host Moira Gunn talks with Nanomix President and CEO David Ludvigson about the development of 15-minute point-of-care SARS-CoV-2 antigen and antibody tests that will run on the Nanomix eLab analyzer.
• April 8, 2020
  Nanōmix Awarded BARDA Contract for Development of Rapid, Mobile, Point-of-Care Assays to Detect COVID-19 Infection  (link)
• April 6, 2020
  San Francisco Business Times: How California plans to break the logjam for COVID-19 tests.  (link)
  Staff Reporter Ron Leuty writes about a California task force that is working to make adequate numbers of COVID-19 tests available, including serology-based tests. The story describes Nanomix's work to develop rapid, point-of-care COVID-19 tests, and quotes CEO David Ludvigson who says, "The serological testing is really going to be important … for getting the world back moving again."
• April 3, 2020
  KGO7 (ABC), Coronavirus Test: East Bay company to have hand-held COVID-19 testing devices ready by next month.  (link)
  This story highlights the Nanomix in-development COVID19 tests, including footage from the Nanomix laboratories in Emeryville, Calif.

• December 5, 2019
  Nanōmix Receives CE Mark for Diagnostic Panel that Aids in Rapid Identification of Serious, Life-Threatening Infections.
• November 2, 2019
  Rapid Triage Testing Could Improve Outcomes for Patients with Acute Kidney Injury Contributed by David Ludvigson and Nam Tran, PhD.  (link)
• June 25, 2019
  Nanōmix today announced MedTech Innovator has selected Nanomix as one of the 50 Best-in-Class Startups for 2019.
• January, 2019
  Smarter, Faster Sepsis Testing - Point-of-care diagnostics for sepsis would catalyze early intervention Contributed Commentary by David Ludvigson.  (link)

• May 16, 2018
  For Sepsis, Triage Testing Would Improve Patient Outcomes. Contributed Commentary by David Ludvigson.  (link)
• April 25, 2018
  Focus On: Med/Surg: Screening for Sepsis. New prospects for improving the rapid diagnosis of sepsis By David Ludvigson  (link)

• November 9, 2017
  Nanōmix Announces Equity Financing and Collaboration with Hong Kong-Beijing based World Technology East and RedPharm Biotechnology Companies  (PDF)
• July 27, 2017
  Rapid testing aids in the early diagnosis of sepsis  (PDF)
• March 7, 2017
  Nanōmix Awarded U.S. Patent for "Nanoelectronic Electrochemical Test Device"  (PDF)
• January 19, 2017
  Nanōmix in the News for its Handheld Device and Rapid Test to Screen for Sepsis

• December 13, 2016
  Nanōmix Advances Rapid Diagnostic Panel to Aid Emergency Evaluation of Sepsis  (PDF)
• October 12, 2016
  Nanōmix Awarded US Patent for Nanōmix eLab^®® System.  (PDF)

• November 5, 2015
  Nanōmix Awarded Chemical Sensor Cartridge Patent.  (PDF)
• August 17, 2015
  Nanōmix Appoints Larry K. Wray, Ph.D. as VP of Development.  (PDF)

• November 25, 2014
  Nanōmix receives ISO:13485 certification.  (PDF)
• November 17, 2014
  Nanōmix appoints Dr. Tom Richards as Senior Advisor  (PDF)
• November 6, 2014
  Nanōmix chairman Garrett Gruener participates in a roundtable discussion on technologies to stop Ebola
• October 23, 2014
  Nanōmix's multiplexed Ebola test highlighted as a potential tool in the fight against Ebola
• October 16, 2014
  Detection of Ebola Virus: Discussion of PCR Testing and Immunoassay Testing Using the Nanōmix eLab^® System  (PDF)
• October 06, 2014
  The Nanōmix test could play a crucial role in differentiating Ebola from other sicknesses
• October 4, 2014
  Nanōmix and Corgenix Team Up to Develop Tests to Control the Ebola Spread and Future Outbreaks
• September 12, 2014
  Nanōmix Supports Sepsis Awareness  (PDF)
• June 30, 2014
  Nanōmix Appoints New CFO  (PDF)
• June 18, 2014
  Nanōmix Awarded Nanostructure Sensor Patent  (PDF)
• March 17, 2014
  Nanōmix Awarded Design Patent in Japan  (PDF)
• January 30, 2014
  Nanōmix Closes Private Financing  (PDF)

• September 10, 2013
  Nanōmix Featured in Frost & Sullivan's Cooltech Session at GIL 2013  (PDF)
• July 17, 2013
  Nanōmix at AACC 2013 in Houston  (PDF)
  Abby Jones from Corgenix will be presenting at the July 31 Poster Session on a Corgenix and Nanomix Collaboration for the development of a handheld mulitplex POC diagnostic for Lassa fever, Dengue fever and Ebola Hemorrhagic Fever.
• June 1, 2013
  Nanōmix Appoints President and CEO  (PDF)
• March 18, 2013
  Nanōmix Awarded Patent for Carbon Nanotube Sensor Technology  (PDF)
• February 11, 2013
  Nanōmix Inc. Initiates Clinical Testing  (PDF)

• October 30, 2012
  Nanōmix Inc. awarded NASA development subcontract  (PDF)